Back to search
FDAFDA · Food and drugs·Recall number D-1546-2022

ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-167-01

Published October 5, 2022 · Recall initiated: August 23, 2022

Summary

FDA records drug Class III recall D-1546-2022, published October 5, 2022 and initiated August 23, 2022. Recalling firm: Leading Pharma, LLC; Status: Terminated; Reported quantity: 960 bottles (100 capsules); Lot: Lot#: B14221, Exp. Date 02/2023. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules

What to do

Voluntary: Firm initiated · Letter

Get an email if CLOMIPRAMINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CLOMIPRAMINE HYDROCHLORIDE
Manufacturer
Leading Pharma, LLC
Distributor
Nationwide within the United States
UPC
0369315167014
Lot
Lot#: B14221, Exp. Date 02/2023
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-167-01 recalled?

Yes. FDA published recall D-1546-2022 on October 5, 2022. Reported hazard: Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CLOMIPRAMINE HYDROCHLORIDE. UPC: 0369315167014.